Patients with high-risk acute coronary syndromes have been shown to benefi t from a strategy of early invasive catheterisation, and this is refl ected in the US and European guidelines. However, the recently reported long-term follow-up from the Invasive versus Conservative Treatment in Unstable Coronary Syndromes (ICTUS) trial shows that even patients with elevated troponin may not benefi t substantially from an early invasive strategy, compared with a "selective invasive" strategy, in the context of optimum medical therapy. 1 Selected trials have suggested benefi ts from very early routine catheterisation, 2 3 particularly among high-risk patients, 3 although it remains unclear whether immediate catheterisation and revascularisation has measurable benefi ts compared with the more convenient approach of catheterisation the next working day.
The Angioplasty to Blunt the Rise of Troponin in Acute Coronary Syndromes Randomized for an Immediate or Delayed Intervention (ABOARD) trial was designed to Christopher B. Granger 
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Evidence-Based Medicine February 2010 | volume 15 | number 1 | address this question. Patients who were medium or high risk (TIMI risk score ≥3) were randomly assigned to immediate (median, 70 minutes) or delayed (21 hours) catheterisation. The primary outcome, peak troponin during hospitalisation, was not found to differ between the groups. Neither was the key secondary outcome of death, myocardial infarction or urgent revascu larisation at 1 month. The investigators conclude that there is no advantage to the immediate strategy in reducing myocardial infarction as defi ned by peak troponin.
A fundamental principle in evidence-based medicine is that best evidence must be derived from adequately sized trials assessing the treatment effect on clinically relevant outcomes. The ABOARD trial did not do this; it used a biomarker of myocardial necrosis-troponin-to measure treatment effect. The investigators do not comment on the effect size that would have been required to detect a statistically signifi cant difference given their sample size, but the wide interquartile range of troponin suggests a relative reduction of >30% in troponin would have been necessary, which is a very large relative effect. Moreover, peak troponin is an interesting but unproven "surrogate" outcome in this type of a trial. Thus, although this approach is appropriate for generating hypotheses and adds to our knowledge, it is not adequate to guide therapy. A key secondary outcome was the composite of death, reinfarction and urgent revascularisation at 1 month. There were a total of 42 such events in the trial, which makes this study grossly underpowered to detect plausible treatment differences. The investigators provide little perspective on these limitations in their discussion.
Do the results of this trial have any implications, then, for the practice of medicine? The authors point out that the trial had some important strengths: it included an arm of very early intervention and is refl ective of today's practice; nearly all patients underwent catheterisation at some point; medical treatment was excellent and included high-dose clopidogrel. As current practice guidelines allow discretion in the timing of the early invasive approach, more information on outcomes with various timing strategies is important. This trial provides systematic data on outcomes with an immediate cathet erisation
) catheterisation may be a reasonable option, with the caveat that this trial in isolation simply had too few patients and too few events to be used to change practice.
The trial is consistent with the largest study of the timing of cardiac catheterisation, the Timing of Intervention in Acute Coronary Syndromes (TIMACS) trial, which had nearly 10 times the sample size of ABOARD and showed similar outcomes with early (14 hours) versus delayed (50 hours) catheterisation after presentation. In that trial, patients at high risk (estimated risk of in-hospital death >3% by the GRACE risk score) had a 35% relative risk reduction for death, myocardial infarction or stroke, compared with little treatment effect in patients at lower risk (p = 0.01 for heterogeneity). ABOARD was consistent with TIMACS in showing that the immediate strategy had numerically fewer patients with recurrent ischaemia.
The available evidence suggests that relatively early catheterisation and intervention (within 24 hours) benefi ts high-risk patients and that very early (or immediate) catheterisation appears to be an acceptable approach. Further studies are required to compare the costs and resource use of the different catheterisation timing strategies.
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